Meeting
2022 ASCO Annual Meeting
Phase I study of the anti-BTLA antibody icatolimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas.
Authors
Jun Ma
Department of Hematology & Oncology, Harbin Institute of Hematology & Oncology, Harbin, China
Jun Ma , Yan Xie , Huilai Zhang , Yuqin Song , Weili Zhao , Yali Pan , Feiwu Ran , Hui Feng , Sheng Yao , Patricia Keegan , Jun Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Other Lymphoma
Clinical Trial Registration Number
NCT04477772
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7578)
DOI
10.1200/JCO.2022.40.16_suppl.7578
Abstract #
7578
Poster Bd #
230
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
CeNtuRIOn: Rucaparib (R) with nivolumab (N) and ipilimumab (I) in patients (pts) with relapsed ovarian cancer (ROC)—Results of an initial safety cohort.
First Author: Marcia Hall
Poster
2022 ASCO Annual Meeting
Phase Ia dose-escalation study of the anti-BTLA antibody icatolimab as a monotherapy in patients with advanced solid tumor.
First Author: Russell J. Schilder
Poster
2023 ASCO Annual Meeting
GNC-038, a tetra-specific antibody, in patients with R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale.
First Author: Jianxiang Wang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk